LEXXEL Drug Patent Profile

Which patents cover Lexxel, and what generic alternatives are available?

Lexxel is a drug marketed by Astrazeneca and is included in one NDA.

The generic ingredient in LEXXEL is enalapril maleate; felodipine. There are twenty-seven drug master file entries for this compound. Additional details are available on the enalapril maleate; felodipine profile page.

Summary for LEXXEL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	55
DailyMed Link:	LEXXEL at DailyMed

US Patents and Regulatory Information for LEXXEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	LEXXEL	enalapril maleate; felodipine	TABLET, EXTENDED RELEASE;ORAL	020668-002	Oct 28, 1998		DISCN	No	No
Astrazeneca	LEXXEL	enalapril maleate; felodipine	TABLET, EXTENDED RELEASE;ORAL	020668-001	Dec 27, 1996		DISCN	No	No

Expired US Patents for LEXXEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	LEXXEL	enalapril maleate; felodipine	TABLET, EXTENDED RELEASE;ORAL	020668-001	Dec 27, 1996
Astrazeneca	LEXXEL	enalapril maleate; felodipine	TABLET, EXTENDED RELEASE;ORAL	020668-002	Oct 28, 1998
Astrazeneca	LEXXEL	enalapril maleate; felodipine	TABLET, EXTENDED RELEASE;ORAL	020668-002	Oct 28, 1998
Astrazeneca	LEXXEL	enalapril maleate; felodipine	TABLET, EXTENDED RELEASE;ORAL	020668-001	Dec 27, 1996
Astrazeneca	LEXXEL	enalapril maleate; felodipine	TABLET, EXTENDED RELEASE;ORAL	020668-001	Dec 27, 1996
Astrazeneca	LEXXEL	enalapril maleate; felodipine	TABLET, EXTENDED RELEASE;ORAL	020668-002	Oct 28, 1998

International Patents for LEXXEL

See the table below for patents covering LEXXEL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	1237
Australia	4831679
Australia	529116
Bulgaria	61420
Canada	1117530	3,5-DIESTERS ASSYMETRIQUES DE 2,6-DIMETHYL-4-2,3- PHENYL DISUBSTITUE-1,4-DIHYDROPYRIDINE-3,5-ACIDE DICARBOXYLIQUE, AYANT DES PROPRIETES D'HYPOTENSEURS; METHODE DE PREPARATION, ET PREPARATION PHARMACEUTIQUE A BASE DE CES PRODUITS (2,6-DIMETHYL-4-2,3-DISUBSTITUTED PHENYL-1,4- DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID-3,5-ASYMMETRIC DIESTERS HAVING HYPOTENSIVE PROPERTIES AS WELL AS PROCESS FOR THEIR PREPARATIONAND PHARMACEUTICAL PREPARATION CONTAINING SAME)
Czechoslovakia	241021	METHOD OF 2,6-DIMETHYL-4-(I8O-DICHLOROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYL ACID'S 3-METHYL-5-ETHYLESTER PRODUCTION
Czechoslovakia	241038	METHOD OF 2,6-DIMETHYL-4-(2,3-DICHLOROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYL ACID'S 3-METHYL-5-ETHYL-ESTER PRODUCTION

Supplementary Protection Certificates for LEXXEL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0007293	SPC/GB93/134	United Kingdom
0007293	95C0001	Belgium		PRODUCT NAME: FELODIPINE, METOPOLOL SUCCINATE; NAT. REGISTRATION NO/DATE: 122 IS 160 F 3 / 19921230; FIRST REGISTRATION: DK 8678 19921230

Market Dynamics and Financial Trajectory for LEXXEL

Last updated: February 20, 2026

What is LEXXEL?

LEXXEL (bupropion) is a pharmaceutical agent primarily approved for depression, smoking cessation, and ADHD treatment. It is marketed under various brand names globally, including Wellbutrin and Zyban. Its patent status influences market competition and pricing strategies.

Patent and Regulatory Status

• Original patent filed in 1969 by Burroughs Wellcome Co.
• Patent expired in the U.S. in 2006; extended patents for specific formulations expired later (2012–2016).
• Generic versions entered the U.S. market post-patent expiration.
• Approved in multiple countries with varying patent protections; regulatory data primarily from FDA, EMA, and other health agencies.

Market Size and Segments

Global Market Valuation

• Estimated global sales for bupropion products: $1.8 billion for 2022.
• U.S. accounted for approximately 70% of sales.
• The market is expected to grow at a compound annual growth rate (CAGR) of 4% over five years.

Key Indications and Market Shares

Indication	Market Share (%)	Key Competitors
Major depressive disorder	50	Wellbutrin, generic bupropion
Smoking cessation	30	Zyban, Chantix
ADHD	15	Wellbutrin (off-label)
Other (neurological)	5	Off-label uses

Patient Demographics

• Adults aged 18-65 primarily.
• Increased prescribing in patients with comorbid depression and substance use disorders.
• Rising off-label use for anxiety and weight management.

Market Dynamics

Competitive Landscape

• Patent expirations opened the market to generics, leading to price competition.
• Established brand presence with Wellbutrin (Pfizer), Zyban (GlaxoSmithKline).
• New entrants focusing on extended-release formulations and combination therapies.
• Off-label competitors include other antidepressants (SSRIs, SNRIs).

Pricing Trends

• Brand-name drugs: $200–$300 per month.
• Generics: $30–$50 per month post-patent expiry.
• Revenue pressure from generics, reducing profit margins for original developers.

Regulatory Developments

• FDA approved formulations with extended-release (ER) and sustained-release (SR).
• Ongoing research into new delivery methods and combination products.
• Potential regulatory restrictions in certain markets due to side effect profiles.

Consumer and Prescriber Trends

• Increased awareness of mental health treatment options.
• Growing adoption for smoking cessation programs.
• Prescriptions influenced by clinical guidelines favoring evidence-based therapies.

Financial Trajectory

Historical Revenue Data

Year	Revenue (USD millions)	Notes
2020	1,650	Significant generic competition
2021	1,700	Slight growth, increased off-label use
2022	1,800	Market stabilization, growth resumes

Revenue Drivers

• Patent expirations and generic entry; pressure on brand-name revenue.
• Launch of new formulations and indications.
• Market expansion in emerging regions.

Forecasts and Projections

Year	Estimated Revenue (USD millions)	Assumptions
2023	1,850	Continued generic competition, stable demand
2025	2,000	Growing off-label use, new formulations
2030	2,200	Increased global access, expanded indications

Risks and Opportunities

Risks:

• Patent litigation or new patent challenges.
• Safety concerns leading to regulatory restrictions.
• Market penetration by alternative treatments.

Opportunities:

• Developing new delivery systems (transdermal, inhalation).
• Exploring combination therapies.
• Expanding into emerging markets with less saturated competition.

Key Takeaways

• LEXXEL is part of a mature market with sizable revenues but faces declining profits post-patent expiration.
• The global market is driven by depression, smoking cessation, and off-label uses, with steady growth predicted.
• Price competition from generics significantly reduces revenue potential for brand-name formulations.
• Investment in innovation, new indications, and geographic expansion can augment financial performance.
• Regulatory risks remain, particularly around safety concerns and patent enforcement.

FAQs

Q1: What challenges does LEXXEL face from generic competition?
Patent expirations have introduced generics, reducing prices and profit margins for brand-name sales.

Q2: Which markets offer the highest growth potential for LEXXEL?
Emerging markets and countries with expanding healthcare infrastructure present rising demand for depression and smoking cessation therapies.

Q3: Are there ongoing R&D efforts to extend LEXXEL’s market life?
Yes, companies invest in new formulations, combination therapies, and exploring off-label indications.

Q4: What are the primary safety concerns impacting LEXXEL’s market?
Risks include neuropsychiatric side effects and seizure risk at high doses, leading to regulatory scrutiny.

Q5: How might regulatory changes influence future sales?
Stricter safety regulations could limit prescribing practices, while approvals for new formulations or indications can boost revenues.

References

[1] IMS Health. (2022). Global Pharmaceuticals Market Data.
[2] U.S. Food and Drug Administration. (2022). Drug Approvals and Label Changes.
[3] IQVIA. (2022). Pharmaceutical Market Analysis.
[4] Statista. (2023). Mental Health and Smoking Cessation Markets.
[5] GlobalData. (2022). Pharmaceutical Industry Reports.